According to the Zhitong Finance App, Xinrui Pharmaceuticals (06108.HK) announced interim results for the six months ended June 30, 2026, with revenue of HK$113 million, up 153.7% year on year; net loss due to company owners was HK$3,565 million, a decrease of 52.2% year on year; basic loss per share was 1.78 HK cents.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.